{
    "Trade/Device Name(s)": [
        "APOLOWAKO HbA1c",
        "APOLOWAKO GLU"
    ],
    "Submitter Information": "Wako Diagnostics",
    "510(k) Number": "K080123",
    "Predicate Device Reference 510(k) Number(s)": [
        "K904082",
        "K011933"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CFR",
        "LCP"
    ],
    "Summary Letter Date": "June 24, 2008",
    "Summary Letter Received Date": "June 30, 2008",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 862.1345",
        "21 CFR 864.7470"
    ],
    "Regulation Name(s)": [
        "Glucose test system",
        "Glycosylated hemoglobin assay"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Hemoglobin A1c",
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Whole blood"
    ],
    "Specimen Container(s)": [
        "EDTA tube",
        "Heparin tube"
    ],
    "Instrument(s)/Platform(s)": [
        "APOLOWAKO analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Colorimetric enzyme-based (glucose)",
        "Absorbance immune inhibition (HbA1c)"
    ],
    "Methodologies": [
        "Colorimetric",
        "Enzyme-based",
        "Immune inhibition"
    ],
    "Submission Type(s)": [
        "Analyzer",
        "Reagent",
        "Calibrator",
        "Kit"
    ],
    "Document Summary": "FDA 510(k) summary for APOLOWAKO HbA1c and APOLOWAKO GLU for quantitative measurement of hemoglobin A1c and glucose in whole blood using APOLOWAKO analyzer",
    "Indications for Use Summary": "Quantitative determination of hemoglobin A1c (%) and glucose in whole blood for monitoring long-term glucose control in diabetes and for diagnosis/treatment of carbohydrate metabolism disorders",
    "fda_folder": "Clinical Chemistry"
}